Your feedback on video

Surprise suitor for Elan

Feb 25 2013  Last week, Elan announced plans to launch new acquisitions; this week it has become the target of Royalty Pharma, a US specialist pharmaceutical investment vehicle. A deal would value the Dublin-based pharmaceutical business at $6.6bn, and catches Elan at a moment of weakness. Lex's Stuart Kirk and Vincent Boland consider whether shareholders will be attracted by the offer.  (3m 14sec)
Related Links:
Credits:
Produced by Nalini Sivathasan. Filmed by Rod Fitzgerald.

  • Editor's Choice
  • Next in section
  • Latest
  • Most popular

Companies

Markets

World

Global Economy

Management

Personal Finance

Life & Arts